Doximity (NYSE:DOCS): The Pharma Platform I’m Still Sitting With — But Not Comfortably
Doximity has been sitting in my portfolio under “healthcare drag” for too long without a proper post. After digging into it properly, the business model is more interesting — and more complicated — than most coverage suggests. Here’s my honest breakdown of what’s keeping me in, what worries me about the management, and what May 13 needs to show me.